**Women’s CVD Part 2: Right Care Heart Attack & Stroke Prevention (5.9.22): Women’s CVD from the VA’s Perspective; Broken-Heart Syndrome; Review of Policy Recommendations for Early Identification & Treatment of Women’s CVD Risk Factors.**

December 4, 2024 – August 7, 2025

**Error! Unknown op code for conditional.**

**Target Audience**

Specialties – Emergency Medicine, Family Medicine, Medicine, Neurology, Obstetrics & Gynecology, Radiological Sciences, Other

**Activity Objectives**

1 Identify risks specific to women for cardiovascular disease and recognize risks specific to women military veterans

1 Recognize Takotsubo cardiomyopathy (Broken Heart Syndrome) and understand why it is more prevalent in women than men

2 Identify and implement strategies for secondary prevention of cardiovascular disease in women

3 Be able to identify sex differences in the autonomic nervous system

3 Perform early identification and treatment of women’s cardiovascular risk factors

**Accreditation Statement**

This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of the University of California, Irvine School of Medicine and UC Berkeley. The University of California, Irvine School of Medicine is accredited by the ACCME to provide continuing medical education for physicians.

**Designation Statement**

The University of California, Irvine School of Medicine designates this Enduring Material for a maximum of 1.00 *AMA PRA Category 1 Credit(s)*™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

**California Assembly Bill 1195 and 241**

This activity is in compliance with California Assembly Bill 1195 and 241, which require CME activities with patient care components to include curriculum in the subjects of cultural and linguistic competency & implicit bias. It is the intent of AB 1195 and AB 241 to encourage physicians and surgeons, CME providers in the State of California, and the Accreditation Council for Continuing Medical Education to meet the cultural and linguistic concerns of a diverse patient population and reduce health disparities through appropriate professional development. Please see the CME website, <https://www.meded.uci.edu/CME/> for AB 1195 and AB 241 resources.











**MOC Statement(s)**

Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 1.00 MOC point(s) in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.ABMS

**Faculty & Planner Disclosures**

University of California, Irvine School of Medicine Continuing Medical Education adheres to the ACCME’s Standards for Integrity and Independence in Accredited Continuing Education. Any individuals in a position to control the content of a CE activity, including faculty, planners, reviewers, or others are required to disclose all relevant financial relationships with ineligible entities (commercial interests). All relevant conflicts of interest have been mitigated prior to the commencement of the activity.

|  |  |  |
| --- | --- | --- |
| **Name of individual** | **Individual's role in activity** | **Nature of Relationship(s) / Name of Ineligible Company(s)** |
| Sarah Epstein, PhD | Planning Commitee Member | Nothing to disclose - 10/23/2024 |
| Hattie Hanley, Other | Course Director, Planning Commitee Member | Nothing to disclose - 10/23/2024 |
| Karen M Sky, MD, FACP, FACR | Activity Coordinator, Planning Commitee Member | Nothing to disclose - 10/23/2024 |
| Nathan D. Wong, PhD, MPH | Planning Commitee Member | Grant or research support-Novartis Corporation Pharmaceuticals|Consulting Fee-Novartis Corporation Pharmaceuticals|Consulting Fee-Amgen, Inc.|Consulting Fee-Ionis Pharmaceuticals|Grant or research support-Novo Nordisk (Any division)|Consulting Fee-Heart Lung|Grant or research support-Amgen, Inc.|Speakers Bureau-Novartis Corporation Pharmaceuticals - 11/08/2024 |
| Jan Hirsch, PhD | Planning Commitee Member | Nothing to disclose - 10/23/2024 |
| William Bommer, MD | Planning Commitee Member | Nothing to disclose - 10/23/2024 |
| Sara Johnson, MD | Faculty | Nothing to disclose - 12/02/2024 |
| Eveline Stock, MD | Faculty | Grant or research support-Novartis Corporation Pharmaceuticals - 12/02/2024 |
| Catrina Taylor, PhD, California Department of Public Health | Faculty | Nothing to disclose - 02/23/2024 |
| Carolyn M Clancy, MD | Faculty | Nothing to disclose - 02/28/2024 |
| C. Noel Bairey Merz, MD | Faculty | Consulting Fee-NIH SREA CSR|Consulting Fee-CDMRP Department of Defense CSR|Stocks or stock options, excluding diversified mutual funds-iRhythm|Honoraria-American College of Cardiology|Honoraria-Cottage Hospital 3rd Annual CV Symp|Honoraria-University of Arizona lecture|Honoraria-Scripps Lecture|Honoraria-Christ Hospital 3rd Annual CV Symp|Grant or research support-CDMRP Department of Defense WARRIOR|Grant or research support-NHLBI subcontract to Research Triangle Institute Internation NuMoM2b HHS|Grant or research support-NHLBI R01 WISE preHFpEF|Grant or research support-NIA U54 MAE WEST|Grant or research support-Foundation Takotsubo Registry|Grant or research support-SHI Takotsubo Brain Heart|Grant or research support-Phillips CFT Project|Grant or research support-Foundation WISE HFpEF - 02/29/2024 |

**Agenda**

**[INSERT AGENDA HERE MANUALLY]**

**Acknowledgement of Commercial Support**

No commercial support has been received for this activity.